Washington, DC (May 24, 2017) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the announced creation of an Opioid Policy Steering Committee at the Food and Drug Administration (FDA):
“We commend Commissioner Gottlieb for his leadership in establishing the Opioid Policy Steering Committee. His swift action in this area demonstrates that addressing the growing opioid crisis will be a top priority for the Agency under his leadership.
“America’s biopharmaceutical companies are committed to finding solutions to help curb opioid abuse. Several of our member companies are developing non-addictive, next generation therapies with the potential to transform the standard of care for pain management. They are also working to develop new opioid formulations that prevent or deter improper use, such as tamper-proof pills, and taking steps to increase their prescriber education efforts.
“We stand ready to work with Commissioner Gottlieb and the Committee to better meet the needs of patients with chronic and acute pain.”
Upcoming BIO Events
BIO International Convention | BIO World Congress on Industrial Biotechnology |
###